

In the Name of God the Compassionate

Curriculum Vita (CV)

Name: Zahra

Family: Tolou_Ghamari

Nationality: Iranian

Doctor of Pharmacy

Doctor of Philosophy (PhD) in Clinical Pharmacy

Department of Medicine, King's College School of Medicine

King's College Hospital, University of London.

CONTACT ADDRESS:

Isfahan University of Medical Sciences

Phone: +98-09131046788

EDUCATION

Pharm D: Iran

Ph.D: United Kingdom; London, King's College School of Medicine & King's College Hospital, London, (Clinical Pharmacy/Clinical Pharmacokinetics), 1999 Research Thesis:

EXPERIENCES

- 1) Resident of Clinical Pharmacy, King's College Hospital. United Kingdom, London, England.
- 2) Assistant Professor, Isfahan University of Medical Sciences Iran.
- 3) Associate Professor, Isfahan University of Medical Sciences Iran.

WORKSHOPS

1. a: English Language courses: 5 June – 1 Sep 1994 (3 months). United Kingdom, London.
b: In sessional course Jan 1995. United Kingdom, London.
2. British association of the study of liver disease (BASAL), Annual Scientific Programme Room 3019, King's College Chelsea (255 King's Road, London SW10, UK): 23-24 February 1995. United Kingdom, London.
3. Postgraduate training workshops; Scientific Data Management; organised by Mr Ian Chivers, Chesham building; (Strand Street, London, UK) 29th February 1996. United Kingdom, London.
4. Symposium program challenges in immunosuppression, Differentiation is the key; organised by Fujisawa/JAPAN; Shrigley Hall Hotel and Country Club, Shrigley Park, Pott Shrigley Nr Macclesfield; (Cheshire, SK10 5SB, UK). 11-12 March 1996.
5. Liver disease-looking towards the millennium; 30 anniversary meeting of the liver unit and institute fellows, 1966-1996; Organised by liver unit, King's College Hospital; (New theatre, King's College London, Strand Street) 15-16 April 1996. United Kingdom, London.

6. Poster day (Pharmacokinetic of Tacrolimus); organised by Medical School, King's College School of Medicine and Dentistry, Friday 26th July 1996. United Kingdom, London.
7. Induction course organised by Medical School, King's College School of Medicine and Dentistry, London, 4-10 January 1997. United Kingdom, London.
8. Pharmacokinetics organised by Rostrum Personal Development, London, 15-17 April 1997. United Kingdom, London.
9. One week workshop in basic pharmacokinetics organised by the University of Manchester, Arosa, Switzerland, 6-11 July 1997.
10. Monday (Research) Wednesday (Immunology) and Friday (Surgical/Anaesthetic) internal research meetings, King's College Hospital, London.
11. Lecturers training workshops for methods of research: Organised by Isfahan Medical Educational Center, 5-8 Esfand 1380.
12. Lecturers training workshops for how to exam medical students? Organised by Isfahan Medical Educational Centre, 26-27 Esfand 1380.

سابقه تدریس در دروس:

فارماکولوژی - واژه شناسی - زبان تخصصی - اخلاق در داروسازی - درمانشناسی - کارآموزی در عرصه بیمارستان - کارآموزی در عرصه داروخانه.

سرپرستی پایان نامه ها:

داروسازی و پزشکی

انجام فعالیتهای دانش پژوهی پژوهشی:

سخنرانیها در مجامع علمی - تخصصی (سویترلند - اطریش - منچستر - برادفورد - لندن) و برگزاری کارگاههای عملی بازآموزی در زمینه داروسازی و پزشکی

شرکت در مجامع علمی و بین المللی:

Chicago: The American association for the study of liver disease:

Veinna: XX international congress of the transplantation society

Perth; Australia: 10th-Asian Pacific Congress of Clinical Biochemistry

Malysia: 8th Cast congress of the Asian society of transplantation

Kyoto: The 18th international congress of clinical chemistry and laboratory medicine

چهارمین کنگره پیوند اعضا ایران اصفهان.

و سایر کنگره های داخلی و خارجی.

ارزیابی، داوری و نظارت بر فعالیتهای پژوهشی

داروی طرحهای تحقیقاتی و مقالات مجلات داخلی و خارجی.

PAPERS PUBLISHED IN JOURNALS

Tadayon F, Shariati A, Tolou-Ghamari Z. Type of vascular anastomosis and early outcome after kidney transplantation. *Urologia*. 2021 Jun.

Mazdak H, Tolou Ghamari Z, Gholampour M. Bladder cancer: total antioxidant capacity and pharmacotherapy with vitamin-E. *Int Urol Nephrol*. 2020. Jul;52 (7):1255-1260. doi: 10.1007/s11255-020-02411-3.

Z Tolou-Ghamari. Prevalence of Colorectal Cancers in Isfahan Province, Iran. *Jentashapir Journal of Health Research* 10 (2). 2019.

Z Tolou-Ghamari. Prevalence of Kidney, Renal Pelvis, and Ureter Cancers in Isfahan Province, Iran. *Journal of Archives in Military Medicine*. 2019

H Mazdak, AK Khorrami, Z Tolou-Ghamari*. Urethral stricture: Investigation of demographic characteristics in two tertiary hospitals in Isfahan/Iran. *American Journal of Experimental and Clinical Research* 6 (3), 355-358. 2019

Z Tolou-Ghamari. Investigation of Genital System Cancers Prevalence in Isfahan, Iran. *Indonesian Journal of Cancer* 13 (2), 25-28. 2019

H Mazdak, Z Tolou-Ghamari*, M Gholumpour. Investigation of bladder cancer incidence in Isfahan, Iran. *Tehran University Medical Journal TUMS Publications* 77 (4), 252-256. 2019

Z Tolou-Ghamari. Thyroid Cancer in Isfahan Province, Iran; Prevalence and Demographic Characteristics. *Jundishapur Journal of Chronic Disease Care*. 2019

F Tadayon, A Shariati, Z Tolou-Ghamari*. Study of 2550 donor-recipient demographic characteristics associated with kidney transplantation in Isfahan Province Iran. *American Journal of Experimental and Clinical Research* 5 (4), 310-313. 2019

Z Tolou-Ghamari*, F Tadayon, H Mazdak. Prevalence of Liver Cancer in Isfahan Province, Iran. *Indonesian Journal of Cancer* 12 (2), 56-59. 2019

Z Tolou-Ghamari. Prevalence of stomach cancer in Isfahan Province, Iran. *Gulf J Oncolog*. 2018 Sep;1(28):42-45.

Z Tolou-Ghamari. Prevalence of lung cancer in Isfahan Province, Iran. *J Egypt Natl Canc Inst*. 2018; 30(2):57-59.

H Mazdak, Z Tolou-Ghamari. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. *Arab journal of urology*. 2018; 16 (2), 206-210.

H Mazdak, Z Tolou-Ghamari. Frequency of genito-urinary tract disorders in a tertiary ospital in Isfahan, Iran. *American Journal of Experimental and Clinical Research*. 2018; (1), 258-262.

Z Tolou-Ghamari. Review of Iranian instruction programs for clinical pharmacy. *American Journal of Experimental and Clinical Research*. 2017; 4 (2), 202-205.

Z Tolou_Ghamari. Atlas of Death for the Main Causes of Neurologic Disorders in a local Hospital in Isfahan/Iran. 2017; *Focus on Sciences* 3(1).

Z Tolou_Ghamari. Spirituality Believing in End Stage Diseases Such as; Genitourinary Cancers, Multiple Sclerosis, Recipients of Liver, Kidney or Heart Transplantations. *Focus on Sciences* 2017; 3(1).

H Mazdak, Z Tolou-Ghamari*. Approach to pharmacotherapy of botulinum toxin A in the field of urology. *American Journal of Experimental and Clinical Research*. 2017; (1); 189-193.

M MohamadiSichani, Z Tolou-Ghamari*. Investigation of urinary neutrophil gelatinase associated lipocalin (NGAL) for early diagnosis of acute kidney injury after percutaneous nephrolithotomy *African Journal of Urology*. 2017; 23 (4).

F Bahrami, P Kashefi, S Abbasi, H Mazdak, Z Tolou_Ghamari. Evaluation of supportive Psychosocial Protocol on Anxiety of the Patients' Families' Located at the Al-Zahra/Isfahan Intensive Care Unit in 2011. *Focus on Sciences* 2017; 3 (3).

S Mohamadirizi, V Shaygannejad, S Mohamadirizi, Z Tolou-Ghamari. The effect of electronic education on knowledge of patients with multiple sclerosis. *Journal of Education and Health Promotion*. 2017; 6.

F Khorvash, F Heidary, M Saadatnia, A Chitsaz, Z Tolou-Ghamari*. Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction. *Journal of research in medical sciences: the official journal of Isfahan*. 2017; 22.

Z Tolou-Ghamari*, H Mazdak. A Review on Clinical Pharmacokinetics of tamsulosin in Patients with Benign Prostatic Hyperplasia. *Jundishapur Journal of Chronic disease Care*. 2017; 6 (1).

MR Najafi, Z Tolou-Ghamari. Analysis of carbamazepine side effects associated with bone metabolism, folate and vitamin B12 serum levels in Isfahan epileptic patients. *American Journal of Experimental and Clinical Research*. 2016; 3 (3), 175-179.

Z Tolou-Ghamari. Investigation of final causes of death in 5360 deceased patients within a teaching hospital in Isfahan, Iran *American Journal of Experimental and Clinical research*. 2016; 3 (2), 161-164.

A Chitsaz, F Khorvash, Z Tolou-Ghamari*, A Gholamrezaei. Types of dizziness and its relationship with psychological symptoms in patients with chronic dizziness. *American Journal of Experimental and Clinical Research*. 2016; 3 (1), 141-145.

Z Tolou-Ghamari*, M Mohammadi, E Parvaneh. Clinical Investigation of levisticum officinale (Lovage) Effectiveness' in Patients with Cystinuria.. *Journal of urology and Research*. . 2016; 3 (6), 1071-75.

M Yazdani, Z Tolou-Ghamari*, M Asadi-Samani, H Mazdak, E Yazdani. Investigation of prostate disorders in 614 patients attended Alzahra urology ward between the years 2013 to 2015 in Isfahan. *Int J Pharm Clin Res*. 2016; 8, 1543-1547.

Z Tolou-Ghamari*, H Mazdak. Pharmacotherapy updates of recombinant tissue plasminogen activator (r-TPA) in acute ischemic stroke.. *Jentashapir Journal of Health research*. 2016; 7 (3).

Z Tolou-Ghamari. Efficacy and toxicity of rituximab in multiple sclerosis. *Archives of Neuroscience*. 2016; 3 (1).

Z Tolou-Ghamari*, H Mazdak. Fingolimod for multiple sclerosis; mechanism of action, safety and toxicity. *Archives of Neuroscience*. 2016; 3 (3).

Z Tolou-Ghamari*, H Mazdak. Review of Warfarin; A Cytochrome P450

metabolizing Drug, in Clinical Practice. Jentashapir Journal of Health Research. 2016; 7 (3).

Z Tolou-Ghamari. Levetiracetam (Keppra): Evidence-Based Polypharmacy in Two Patients With Epilepsy. Jundishapur Journal of Chronic Disease Care. 2016; 5 (2).

Z Tolou-Ghamari*, B Sanei. Prograf Concentrations in Liver Transplantation: correlation With Headache and Other Neurotoxic Complications?. Thrita. 2016; 5 (1).

Z Tolou-Ghamari*, AA Palizban. Laboratory Monitoring of Cyclosporine Pre-dose concentration (C0) After Kidney Transplantation in Isfahan.. Iranian Journal of Medical Sciences. 2015; 28 (2), 81-85.

Z Tolou-Ghamari*, JM Habibabadi, AA Palizban. Evidence-based pharmacotherapy of epilepsy. Archives of Neuroscience. 2015; 2 (1).

35. Z Tolou-Ghamari. Preliminary Evidence-Based Pharmacotherapy of Mitoxantrone for Multiple Sclerosis in an Iranian Population. i. Thrita. 2015; 4 (3).

Z Tolou-Ghamari*, V Shaygannejad, F Ashtari, A Chitsaz, AA Palizban. Preliminary analysis of month of birth in Iranian/Isfahan patients with multiple sclerosis. Advanced biomedical research. 2015; 4.

Z Tolou-Ghamari*, F Ashtari, V Shaygannejad, AA Palizban. Preliminary study on patients located at the Kashani/Isfahan Hospital with multiple sclerosis between the years 2011 and 2013. Advanced biomedical research. 2015; 4.

Z Tolou-Ghamari. Scattering month and day of baby delivery in a retrospective survey linked to 1484 patients with multiple sclerosis.. Archives of Neuroscience. 2015; 2 (3).

Z Tolou-Ghamari. Preliminary Study of Differences Between Prevalence of Multiple sclerosis in Isfahan and its' Rural Provinces. Archives of Neuroscience. 2015; 2 (4).

Z Tolou-Ghamari*, M Mortazavi, AA Palizban, MR Najafi. The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation. Advanced biomedical research. 2015; 4.

Z Tolou-Ghamari*, AA Palizban. Review of sodium valproate clinical and biochemical properties. Zahedan Journal of Research in Medical Sciences. 2015; 17 (8).

Z Tolou-Ghamari. Demographic analysis of patients with multiple sclerosis; individual variability related to the time interval.. Archives of Neuroscience. 2015; 2 (3).

Z Tolou-Ghamari A review of geoepidemiological differences of multiple sclerosis in Iran and other Middle East countries. Archives of Neuroscience. 2015; 2 (3).

Z Tolou-Ghamari*, A Chitsaz. Nerosurgery and Treatment Strategy using Anti-Epileptic Drugs (AEDs) in Postoperative Seizures: A matter of Debate. Journal of research in Medical Sciences. 2014.

SS Beladi-Mousavi, B Bashardoust, H Nasri, A Ahmadi, Z Tolou-Ghamari, Serum uric acid level and its association with cardio-metabolic risk factors in prediabetics. Iran J Kidney Dis. 2014; 8 (5), 359-62.

SS Beladi-Mousavi, B Bashardoust, H Nasri, A Ahmadi, Z Tolou-Ghamari, The theme of the world diabetes day 2014; healthy living and diabetes; a nephrology viewpoint. Journal of nephropharmacology. 2014; 3 (2), 43.

A Chitsaz, Z Tolou-Ghamari*, F Ashtari. Preliminary evaluations related to the Ranges of hematological and biochemical variables in hospitalized patients with stroke. international journal of preventive medicine. 2013; 4 (Suppl 2), S347.

Z Tolou-Ghamari*, V Shaygannejad, F Khorvash. Preliminary investigation of economics issues in hospitalized patients with stroke. International journal of preventive medicine. 2013; 4 (Suppl 2), S338.

Z Tolou-Ghamari*, MR Najafi, JM Habibabadi, M Zare. Preliminarily analysis of

carbamazepine (CBZ) C0 in patients visited Isfahan epileptic clinics. International journal of preventive medicine. 2013; 4 (Suppl 2), S343.

V Shaygannejad, Z Tolou-Ghamari*. What is the real fate of vitamin D in multiple sclerosis? International journal of preventive medicine. 2013; 4 (Suppl 2), S159.

V Shaygannejad, SR Dehnavi, F Ashtari, S Karimi, L Dehghani, Z Tolou-Ghamari*. Study of type A and B behavior patterns in patients with multiple sclerosis in an Iranian population. International journal of preventive medicine. 2013; 4 (Suppl 2), 279.

Z Tolou-Ghamari*, V Shaygannejad, F Ashtari. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the Isfahan Kashani Hospital..International journal of preventive medicine. 2013; 4 (Suppl 2), S274.

Z Tolou-Ghamari*, M Zare, JM Habibabadi, MR Najafi. Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy. International journal of preventive medicine. 2013 ; 4 (Suppl 2), S330.

Z Tolou-Ghamari*, M Zare, JM Habibabadi, MR Najafi. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. Journal of research in medical sciences. 2013.

Z Tolou-Ghamari. Antiepileptic drugs (AEDs) polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug metabolism letters. 2012; 6 (3), 207-12.

Z Tolou-Ghamari. Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: A review on tacrolimus and cyclosporin in organ transplantation. Journal of nephropatholog. 2012; 1 (1), 23.

Asghari GR, Palizban AA, Z Tolou-Ghamari, F Adeli. Contamination of cadmium, lead and mercury on Iranian herbal medicines. Ppharmaceutical Sciences. 2008.

Z Tolou-Ghamari*, J Tredger. .Descriptive pharmacokinetics parameters of tacrolimus in days 3/4 after liver transplantation: P-260 Liver International. 2006; 226, 3-94

Z Tolou-Ghamari, AA Palizban. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.. Saudi medical journal. 2004; 25 (10), 1499.

Z Tolou-Ghamari*, AA Palizban, J Wendon, JM Tredger. Tacrolimus pharmacokinetics And Dosage Prediction Immediately After Liver Transplantation. transplantation. 2004; 78 (2), 383.

Z Tolou Ghamari, AA Palizban. Adverse reaction following cyclosporin administration. Saudi Med J. 2004; 25, 1499-500.

Z Tolou-Ghamari*, AA Palizban, J Wendon, JM Tredger. Pharmacokinetics of tacrolimus on days one or two after liver transplantation. 2004; Transplant Med 16, 112-6

Z Tolou-Ghamari*, AA Palizban, J Wendon, J Tredger. Pharmacokinetics of tacrolimus Immediately after Liver Transplantation. 2004; Transplantation medicine. 112-116 .

Z Tolou-Ghamari*, A Palizban, J Tredger. Modelling tacrolimus AUC in acute and chronic liver disease immediately after transplant. 2004; Transplantation medicine. 2004; 16, 109.

Z Tolou-Ghamari*, AA Palizban, JM Tredger. Clinical monitoring of tacrolimus after iver transplantation using pentamer formation assay and microparticle enzyme I immunoassay. Drugs in R & D. 2004; 5 (1), 17-22.

Z Tolou-Ghamari*, AA Palizban, M Gharavi. Cyclosporin trough concentration-

rejection relationship after kidney transplantation. *Indian journal of pharmacology*. 2003; 35, 395-396.

Z Tolou-Ghamari*, AA Palizban. The history of liver and renal transplantation. *Internet J Pharmacol*. 2003.

Z Tolou-Ghamari, AA Palizban. Structural-based design for metalloenzym inhibitors: helicobacter pylori urease inhibitors. *Scientica Pharmaceutica*. 2001; 69 (3), S294-S295 .

Z Tolou-Ghamari*, J Wendon, JM Tredger. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation. *clinical chemistry and laboratory medicine*. 2000; 38 (11), 1209-1211.

Z Tolou-Ghamari. Monitoring tacrolimus (fk506) in liver transplant recipients: consideration of alternative techniques and the influence of clinical status. University of london . 1999. 350 pages.

Z Tolou-Ghamari, JA Wendon, JM Tredger. Prediction of tacrolimus exposure in liver transplant recipients using abbreviated blood sampling protocols. *Hepatology*. 1998; 8 (4), 735A-735A.

SM Gabe, Z Tolou-Ghamari, P Johnson, R Crane, M Tredger, I Bjamason, O. 31 tacrolimus inhibits mitochondrial function in vivo, affecting intestinal mucosal barrier function and cellular energy derivation ...*Clinical Nutrition*. 1998; 15, 9.

Gabe SM, Bjarnason I., Tolou_Ghamari Z, Tredger JM, Johnson P, Barclay R, williams R, and Silk DBA. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in human. *Gastroenterology*. 1998; 115:67-74.